1. Home
  2. BRW vs CCCC Comparison

BRW vs CCCC Comparison

Compare BRW & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saba Capital Income & Opportunities Fund SBI

BRW

Saba Capital Income & Opportunities Fund SBI

HOLD

Current Price

$6.00

Market Cap

339.5M

Sector

Finance

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.12

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRW
CCCC
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
339.5M
404.7M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
BRW
CCCC
Price
$6.00
$3.12
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $12.20
AVG Volume (30 Days)
204.6K
★ 1.8M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 16.45
EPS
★ N/A
N/A
Revenue
N/A
★ $35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1.02
52 Week Low
$6.03
$1.69
52 Week High
$7.88
$5.17

Technical Indicators

Market Signals
Indicator
BRW
CCCC
Relative Strength Index (RSI) 25.88 30.24
Support Level N/A $2.52
Resistance Level $6.93 $3.20
Average True Range (ATR) 0.08 0.16
MACD -0.02 -0.04
Stochastic Oscillator 3.33 23.24

Price Performance

Historical Comparison
BRW
CCCC

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: